IMPACT OF AGE AND COMORBIDITY ON RISK STRATIFICATION IN IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
- Clara Hjalmarsson1,
- Göran Rådegran2,
- David Kylhammar3,
- Bengt Rundqvist1,
- Jonas Multing1,
- Magnus D. Nisell4 and
- Barbro Kjellström4
- on behalf of SveFPH and SPAHR
- 1Department of Cardiology, Sahlgrenska Academy, Gothenburg University, and Sahlgrenska University Hospital, Gothenburg, Sweden
- 2Department of Clinical Sciences Lund, Cardiology, Lund University, and Skåne University Hospital, Lund, Sweden
- 3Department of Clinical Physiology and Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden
- 4Cardiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden
- Clara Hjalmarsson MD, PhD, The Department of Cardiology, Blå Stråket 3, 1st Floor, Sahlgrenska University Hospital, SE-405 30 Göteborg, Sweden. E-mail: clara.hjalmarsson{at}vgregion.se
Abstract
Background. Recent reports from worldwide pulmonary hypertension registries show a new demographic picture of the idiopathic pulmonary arterial hypertension (IPAH) population, with an increasing prevalence among the elderly.
Aim. To investigate the effect of age and comorbidity on risk stratification and outcome of patients with incident IPAH.
Methods and results. The study population (n=264) was categorized in four age groups; 18–45, 46–64, 65–74, and ≥75 years. Individual risk profile was determined according to a risk assessment instrument, based on the ESC/ERS guidelines. Change in risk group from baseline to follow-up (median 5 months), and survival were compared across age groups. In the two youngest age groups, a significant number of patients improved (18–45 years; Z = −4.613, p <0.001 and 46–64 years; Z= −2.125, p=0.034), but no significant improvement was found in the older patients. Five-year survival was highest in patients 18–45 years (88%), while the survival rates were 63%, 56%, and 36% for patients in the groups 46–64, 65–74 and ≥75 years, respectively (p<0.001). Ischaemic heart disease and kidney dysfunction independently predicted survival.
Conclusion. These findings highlight the importance of age and specific comorbidities as prognostic markers of outcome, in addition to established risk assessment algorithms.
Abstract
Change in risk category at follow-up and specific comorbidity predict survival in IPAH across age groups
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Hjalmarsson reports personal fees from Actelion Pharmaceuticals Sweden, outside the submitted work.
Conflict of interest: Dr. Rådegran reports grants from Actelion Pharmaceuticals Sweden AB, grants from GlaxoSmith-Kline, personal fees from Actelion Pharmaceuticals Sweden AB, personal fees from GlaxoSmith-Kline, personal fees from Bayer Health Care, personal fees from Actelion Pharmaceuticals Sweden AB, personal fees from GlaxoSmith-Kline, personal fees from Bayer Health Care, non-financial support from Actelion Pharmaceuticals Sweden AB, non-financial support from GlaxoSmith-Kline, non-financial support from Bayer Health Care, non-financial support from Pfizer, non-financial support from United Therapeutics, non-financial support from Novartis, outside the submitted work.
Conflict of interest: Dr. Kylhammar reports personal fees from Actelion Pharmaceuticals Sweden, personal fees from GlaxoSmith-Kline, grants from Actelion Pharmaceuticals Sweden, grants from Pfizer, grants from Bayer Health Care, outside the submitted work.
Conflict of interest: Dr. Rundqvist reports non-financial support from Actelion Pharmaceuticals Sweden AB, non-financial support from GlaxoSmith-Kline, non-financial support from Bayer Health Care, non-financial support from United Therapeutics, outside the submitted work.
Conflict of interest: Mr. Multing has nothing to disclose.
Conflict of interest: M.N. reports personal lecture fees from Actelion Pharmaceuticals Sweden AB, Pfizer, Bayer Health Care, NordicInfu Care, Novartis, Astra Zeneca, Glaxo-SmithKline, Boehringer Ingelheim, and Takeda. M.N. has been the primary or co-investigator in clinical trials for Boehringer Ingelheim, Astra Zeneca, Takeda, Novartis, and United Therapeutics and has been involved in research advisory boards for Actelion Pharmaceuticals Sweden AB, Bayer Health Care, NordicInfu Care, and Glaxo-SmithKline
Conflict of interest: Dr. Kjellström has nothing to disclose.
This is a PDF-only article. Please click on the PDF link above to read it.
- Copyright ©ERS 2018